文献速递心力衰竭与心肌病

环硅酸锆钠在心力衰竭患者螺内酯优化期间管理高钾血症的作用

Sodium Zirconium Cyclosilicate for Management of Hyperkalemia During Spironolactone Optimization in Patients With Heart Failure.
PubMed 文献 · J Am Coll Cardiol · 2024-11-18

REALIZE-K 试验纳入 HFrEF 伴高钾血症患者,开放标签滴定期后随机接受环硅酸锆钠(SZC)或安慰剂 6 个月。SZC 组达到最佳治疗反应的比例为 71%,安慰剂组为 36%(OR 4.45,95%CI 2.89-6.86,P<0.001),且 SZC 改善了前 4 个次要终点,但临床结局事件数在 SZC 组更多。

要点

  • SZC 显著提高 HFrEF 患者维持螺内酯≥25 mg/日且血钾正常比例。
  • SZC 降低高钾血症风险及因高钾血症下调或停用螺内酯的风险。
  • 探索性分析中心血管死亡或心衰恶化事件 SZC 组多于安慰剂组,需权衡。

核心结论

  • 在 HFrEF 伴高钾血症患者中,SZC 大幅提高维持最佳螺内酯剂量下血钾正常的比例,并降低高钾血症及螺内酯下调/停药风险。
  • 尽管研究对临床结局把握度不足,SZC 组心衰事件多于安慰剂组,临床决策时应予考虑。

研究设计与样本

  • REALIZE-K 为前瞻性、双盲、随机撤药试验,纳入 NYHA II-IV 级、LVEF≤40%、已接受最佳指南导向治疗(除 MRA)且存在或新发 MRA 诱导高钾血症的 HFrEF 患者。
  • 开放标签滴定期螺内酯目标剂量 50 mg/日,高钾血症者启用 SZC;血钾正常(3.5-5.0 mEq/L)且螺内酯≥25 mg/日者随机接受继续 SZC 或安慰剂 6 个月。
  • 共随机 203 例(SZC 102 例,安慰剂 101 例)。

主要发现

  • 主要终点最佳治疗反应(螺内酯≥25 mg/日且血钾正常、无需高钾血症 rescue 治疗,第1-6月)SZC 组 71% vs 安慰剂组 36%(OR 4.45,95%CI 2.89-6.86,P<0.001)。
  • 随机剂量螺内酯下血钾正常且无需 rescue 治疗:58% vs 23%(OR 4.58,95%CI 2.78-7.55,P<0.001)。
  • 接受螺内酯≥25 mg/日:81% vs 50%(OR 4.33,95%CI 2.50-7.52,P<0.001)。
  • 至高钾血症时间 HR 0.51(95%CI 0.37-0.71,P<0.001);至因高钾血症下调/停用螺内酯时间 HR 0.37(95%CI 0.17-0.73,P=0.006)。
  • 6 个月 KCCQ-CSS 组间无差异(-1.01 分,95%CI -6.64 至 4.63,P=0.72);不良事件(64% vs 63%)与严重不良事件(23% vs 22%)均衡。

关键数值与推荐

  • 最佳治疗反应定义:螺内酯≥25 mg/日下血钾正常且第1-6月无需高钾血症 rescue 治疗。
  • 血钾正常范围定义为 3.5-5.0 mEq/L。

临床怎么用

  • 对 HFrEF 患者使用螺内酯期间出现高钾血症时,可考虑联用 SZC 以维持螺内酯靶剂量。
  • 应用 SZC 优化螺内酯时需警惕探索性分析提示的心衰事件增多信号,个体化评估获益风险。

局限性

  • 研究对临床结局把握度不足,心衰事件差异仅为探索性发现。
  • 样本量较小(共 203 例),随访 6 个月。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Mineralocorticoid receptor antagonists (MRA) improve outcomes in patients with heart failure and reduced ejection fraction (HFrEF) but are underused in clinical practice. Observational data suggest that hyperkalemia is the leading obstacle for the suboptimal use of MRA. OBJECTIVES: This study sought to evaluate the effects of sodium zirconium cyclosilicate (SZC) in optimizing use of spironolactone among participants with HFrEF and hyperkalemia. METHODS: REALIZE-K (Study to Assess Efficacy and Safety of SZC for the Management of High Potassium in Patients With Symptomatic HFrEF Receiving Spironolactone) was a prospective, double-blind, randomized- withdrawal trial in participants with HFrEF (NYHA functional class II-IV; left ventricular ejection fraction ≤40%), optimal guideline-directed therapy (except MRA), and prevalent or incident MRA-induced hyperkalemia. During open-label run-in, participants underwent spironolactone titration (target: 50 mg/day); those with hyperkalemia started SZC. Participants with normokalemia (potassium: 3.5-5.0 mEq/L) on SZC and spironolactone ≥25 mg/day were randomized to continued SZC or placebo for 6 months. The primary endpoint was optimal treatment response (normokalemia on spironolactone ≥25 mg/day without rescue therapy for hyperkalemia [months 1-6]). The 5 secondary endpoints were tested hierarchically. Exploratory endpoints included a composite of adjudicated cardiovascular death or worsening heart failure (HF) events (hospitalizations and urgent visits). RESULTS: Overall, 203 participants were randomized (SZC: 102; placebo: 101). Higher percentage of SZC- vs placebo-treated participants had optimal response (71% vs 36%; OR: 4.45; 95% CI: 2.89-6.86; P < 0.001). SZC (vs placebo) improved the first 4 secondary endpoints: normokalemia on randomization dose of spironolactone and without rescue therapy (58% vs 23%; OR: 4.58; 95% CI: 2.78-7.55; P < 0.001); receiving spironolactone ≥25 mg/day (81% vs 50%; OR: 4.33; 95% CI: 2.50-7.52; P < 0.001); time to hyperkalemia (HR: 0.51; 95% CI: 0.37-0.71; P < 0.001); and time to decrease/discontinuation of spironolactone due to hyperkalemia (HR: 0.37; 95% CI: 0.17-0.73; P = 0.006). There was no between-group difference in Kansas City Cardiomyopathy Questionnaire-Clinical Summary Score at 6 months (-1.01 points; 95% CI: -6.64 to 4.63; P = 0.72). Adverse events (64% vs 63%) and serious adverse events (23% vs 22%) were balanced between SZC and placebo, respectively. Composite of cardiovascular (CV) death or worsening HF occurred in 11 (11%) participants in the SZC group (1 with CV death, 10 with HF events) and 3 (3%) participants in the placebo group (1 with CV death, 2 with HF events; log-rank nominal P = 0.034). CONCLUSIONS: In participants with HFrEF and hyperkalemia, SZC led to large improvements in the percentage of participants with normokalemia while on optimal spironolactone dose, and reduced risk of hyperkalemia and down-titration/discontinuation of spironolactone. Although underpowered for clinical outcomes, more participants had HF events with SZC than placebo, which should be factored into the clinical decision making. (Study to Assess Efficacy and Safety of SZC for the Management of High Potassium in Patients With Symptomatic HFrEF Receiving Spironolactone; NCT04676646).

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Kosiborod, Cherney, Desai, et al. Sodium Zirconium Cyclosilicate for Management of Hyperkalemia During Spironolactone Optimization in Patients With Heart Failure. J Am Coll Cardiol. 2024. PMID: 39566872. doi:10.1016/j.jacc.2024.11.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。